SCHEMBL4534993

SCHEMBL4534993

COc1c(C(C)(C)C)cc(C(C)(C)C)c(OC)c1C(N)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLRA3 O75311 1/20 0.41
GLRB P48167 1/20 0.41
TNFRSF1A P19438 2/20 0.41
TSHR P16473 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
ALDH1A1 P00352 1/20 0.39
APOBEC3A P31941 1/20 0.39
HTT P42858 1/20 0.39
APOBEC3G Q9HC16 1/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
POLB P06746 3/20 0.38
RIPK2 O43353 2/20 0.37
PTGS2 P35354 1/20 0.37
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
CYP3A4 P08684 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
RARG P13631 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4126173 0.82 GLRA3 (0.57) GLRA3GLRBTNFRSF1ATSHRTDP1
SCHEMBL3579165 0.81 TNFRSF1A (0.51) TNFRSF1ATSHRTDP1ALDH1A1APOBEC3A
SCHEMBL16148683 0.75 NR1H4 (0.36) GLRA3GLRBTNFRSF1ATSHRTDP1
SCHEMBL9577000 0.74 PTPN1 (0.41) TSHRTDP1ALDH1A1APOBEC3AHTT
SCHEMBL6155461 0.72 ALDH1A1 (0.50) TSHRALDH1A1APOBEC3AHTTAPOBEC3G
SCHEMBL29462682 0.72 PTGS2 (0.44) GLRA3GLRBTNFRSF1ATSHRTDP1
SCHEMBL17378865 0.71 CFTR (0.40) TNFRSF1AALDH1A1POLBHPGDKDM4E
SCHEMBL3637333 0.71 TNFRSF1A (0.56) GLRA3GLRBTNFRSF1ACA1CA2
SCHEMBL2772941 0.71 TNFRSF1A (0.53) TNFRSF1ATSHRTDP1ALDH1A1CA1
SCHEMBL14988234 0.69 GLRA3 (0.41) GLRA3GLRBTDP1ALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270470-A1 Compounds I ASTRAZENECA AB (SE) 2009-10-29 US claimed
EP-1881950-A1 NEW COMPOUNDS I AstraZeneca AB (SE) 2008-01-30 EP claimed
WO-2006121391-A1 NEW COMPOUNDS I ASTRAZENECA AB (SE) 2006-11-16 WO claimed
US-20090270470-A1 Compounds I ASTRAZENECA AB (SE) 2009-10-29 US disclosed
EP-1881950-A1 NEW COMPOUNDS I AstraZeneca AB (SE) 2008-01-30 EP disclosed
WO-2006121391-A1 NEW COMPOUNDS I ASTRAZENECA AB (SE) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270470-A1 Compounds I F12, F11, F5 GLRA3 2331/4885GLRB 2118/4885TNFRSF1A 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.